Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations

Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacokinetics 1993-04, Vol.24 (4), p.344-354
Hauptverfasser: HASSLESTRÖM, J, SÄWE, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 354
container_issue 4
container_start_page 344
container_title Clinical pharmacokinetics
container_volume 24
creator HASSLESTRÖM, J
SÄWE, J
description Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process.
doi_str_mv 10.2165/00003088-199324040-00007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75731267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75731267</sourcerecordid><originalsourceid>FETCH-LOGICAL-c308t-55ee3f435b85f132eb3be557c6b77d33f689380b9ee23c6d60b845e156f794283</originalsourceid><addsrcrecordid>eNo9kc1u3CAUhVGVKpmmfYRKLKLs3IIxf9lVUfojpeqmXVuArzskNjiAK-U5-sLFk-mwQZz73QOXgxCm5ENLBf9I6mJEqYZqzdqOdKTZJPkK7SiVusqtOEM7wmjbcC3YBXqT80MlVEvIOTpXnaZEkB36-z2mZe8D4GVv0mxcfKyH4l3GJgx4hmJsnHyesQ94v84mZHyDIRRIcQ-LqSR2z27y4fehIcFUtT-AXQwlebsWHwOO48mpQMYlYuMOVFx89MMGu-qZzEbnt-j1aKYM7477Jfr1-e7n7dfm_seXb7ef7htXRy8N5wBs7Bi3io-UtWCZBc6lE1bKgbFRKM0UsRqgZU4MgljVcaBcjFJ3rWKX6PrFd0nxaYVc-tlnB9NkAsQ195LL-n9CVlC9gC7FnBOM_ZL8bNJzT0m_5dH_z6M_5XGQttb3xztWO8NwajwGUOtXx7rJzkxjMsH5fMK6OoOuL_gH3XSWLA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75731267</pqid></control><display><type>article</type><title>Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>HASSLESTRÖM, J ; SÄWE, J</creator><creatorcontrib>HASSLESTRÖM, J ; SÄWE, J</creatorcontrib><description>Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.2165/00003088-199324040-00007</identifier><identifier>PMID: 8491060</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Administration, Oral ; Adult ; Analgesics ; Biological and medical sciences ; Enterohepatic Circulation - physiology ; Female ; Humans ; Injections, Intravenous ; Male ; Medical sciences ; Middle Aged ; Morphine - administration &amp; dosage ; Morphine - metabolism ; Morphine - pharmacokinetics ; Morphine Derivatives - administration &amp; dosage ; Morphine Derivatives - metabolism ; Morphine Derivatives - pharmacokinetics ; Neuropharmacology ; Pharmacology. Drug treatments</subject><ispartof>Clinical pharmacokinetics, 1993-04, Vol.24 (4), p.344-354</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4689967$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8491060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HASSLESTRÖM, J</creatorcontrib><creatorcontrib>SÄWE, J</creatorcontrib><title>Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Analgesics</subject><subject>Biological and medical sciences</subject><subject>Enterohepatic Circulation - physiology</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Morphine - administration &amp; dosage</subject><subject>Morphine - metabolism</subject><subject>Morphine - pharmacokinetics</subject><subject>Morphine Derivatives - administration &amp; dosage</subject><subject>Morphine Derivatives - metabolism</subject><subject>Morphine Derivatives - pharmacokinetics</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kc1u3CAUhVGVKpmmfYRKLKLs3IIxf9lVUfojpeqmXVuArzskNjiAK-U5-sLFk-mwQZz73QOXgxCm5ENLBf9I6mJEqYZqzdqOdKTZJPkK7SiVusqtOEM7wmjbcC3YBXqT80MlVEvIOTpXnaZEkB36-z2mZe8D4GVv0mxcfKyH4l3GJgx4hmJsnHyesQ94v84mZHyDIRRIcQ-LqSR2z27y4fehIcFUtT-AXQwlebsWHwOO48mpQMYlYuMOVFx89MMGu-qZzEbnt-j1aKYM7477Jfr1-e7n7dfm_seXb7ef7htXRy8N5wBs7Bi3io-UtWCZBc6lE1bKgbFRKM0UsRqgZU4MgljVcaBcjFJ3rWKX6PrFd0nxaYVc-tlnB9NkAsQ195LL-n9CVlC9gC7FnBOM_ZL8bNJzT0m_5dH_z6M_5XGQttb3xztWO8NwajwGUOtXx7rJzkxjMsH5fMK6OoOuL_gH3XSWLA</recordid><startdate>19930401</startdate><enddate>19930401</enddate><creator>HASSLESTRÖM, J</creator><creator>SÄWE, J</creator><general>Adis international</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930401</creationdate><title>Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations</title><author>HASSLESTRÖM, J ; SÄWE, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c308t-55ee3f435b85f132eb3be557c6b77d33f689380b9ee23c6d60b845e156f794283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Analgesics</topic><topic>Biological and medical sciences</topic><topic>Enterohepatic Circulation - physiology</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Morphine - administration &amp; dosage</topic><topic>Morphine - metabolism</topic><topic>Morphine - pharmacokinetics</topic><topic>Morphine Derivatives - administration &amp; dosage</topic><topic>Morphine Derivatives - metabolism</topic><topic>Morphine Derivatives - pharmacokinetics</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HASSLESTRÖM, J</creatorcontrib><creatorcontrib>SÄWE, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HASSLESTRÖM, J</au><au>SÄWE, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>1993-04-01</date><risdate>1993</risdate><volume>24</volume><issue>4</issue><spage>344</spage><epage>354</epage><pages>344-354</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>8491060</pmid><doi>10.2165/00003088-199324040-00007</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0312-5963
ispartof Clinical pharmacokinetics, 1993-04, Vol.24 (4), p.344-354
issn 0312-5963
1179-1926
language eng
recordid cdi_proquest_miscellaneous_75731267
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Administration, Oral
Adult
Analgesics
Biological and medical sciences
Enterohepatic Circulation - physiology
Female
Humans
Injections, Intravenous
Male
Medical sciences
Middle Aged
Morphine - administration & dosage
Morphine - metabolism
Morphine - pharmacokinetics
Morphine Derivatives - administration & dosage
Morphine Derivatives - metabolism
Morphine Derivatives - pharmacokinetics
Neuropharmacology
Pharmacology. Drug treatments
title Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T05%3A19%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Morphine%20pharmacokinetics%20and%20metabolism%20in%20humans%20:%20enterohepatic%20cycling%20and%20relative%20contribution%20of%20metabolites%20to%20active%20opioid%20concentrations&rft.jtitle=Clinical%20pharmacokinetics&rft.au=HASSLESTR%C3%96M,%20J&rft.date=1993-04-01&rft.volume=24&rft.issue=4&rft.spage=344&rft.epage=354&rft.pages=344-354&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.2165/00003088-199324040-00007&rft_dat=%3Cproquest_cross%3E75731267%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75731267&rft_id=info:pmid/8491060&rfr_iscdi=true